VivoSeq
Other

TACE

0

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

TACE is an early-stage landscape with 0 programs across 3 companies. The most active players are Bristol-Myers Squibb, Pfizer, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed15 · 58%
Unknown status4 · 15%
Terminated2 · 8%
Recruiting2 · 8%
No longer available1 · 4%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

26 trials

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06397235·130 enrolled
IL-2 Plus Abatacept in FTD
Recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06395038·10 enrolled
Study in ALS With Abatacept & IL-2
Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06307301·5 enrolled
Abatacept Post-marketing Clinical Study in Japan
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 4·NCT01758198·405 enrolled
Post-marketing Study Assessing the Long-Term Safety of Abatacept
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT02169544·100,000 enrolled
LEA29Y (Belatacept) Emory Edmonton Protocol
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00468403·10 enrolled
A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT03375138·84 enrolled
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT01386359·914 enrolled
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
Completed·Pfizer logoPfizer·Phase 1·NCT03100136·7 enrolled
A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT05981976·174 enrolled
Long Term Experience With Abatacept in Routine Clinical Practice
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT02109666·2,364 enrolled
ISP-TACE Versus TACE for HCC With PVTT
Completed·ZZhongda Hospital·N/A·NCT03108248·126 enrolled
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
Completed·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT07449065·324 enrolled
The Study of Abatacept in Combination With Etanercept
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00162279·141 enrolled
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Completed·Sanofi logoSanofi·Phase 4·NCT01659996·1,394 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)